Abcam extends capabilities with the acquisition of Marker Gene Technologies
LONDON: Abcam Plc, a global innovator in life science reagents and tools, announced the acquisition of the entire issued share capital of Marker Gene Technologies...
Abcam acquires gene editing platform and oncology product portfolio of Applied StemCell
LONDON: Abcam Plc has announced the asset purchase of the gene editing platform and oncology product portfolio of Applied StemCell, Inc. (ASC) for life science...